CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Grindeks AS is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Grindeks AS
Krustpils iela 53
Phone: +371 67083252p:+371 67083252 RIGA, 1057  Latvia Fax: +371 67083505f:+371 67083505
This company is no longer actively traded on any major stock exchange.
Business Summary
Grindeks AS (Grindeks JSC) is a Latvia-based joint stock company engaged in the pharmaceutical sector. The Company is engaged in the production of pharmaceutical and medical products, and phytochemical medicine. The Company offers products, such as: ointments, cough and cold medications, anti-inflammatory agents, gastroenterological agents, tonics and natural health products, as well as active pharmaceutical substances. The Company’s research activities are mainly focused towards the development of cardiovascular medications, neurological medications, anti cancer agents and antiviral drugs. The Company is active domestically and abroad, mainly in the Commonwealth of Independent State countries. It also owns four subsidiaries, Tallin Pharmaceutical Plant JSC, Namu Apsaimniekosanas projekti Ltd, Grindeks RUS Ltd and Kalceks JSC. As of December 31, 2011, the Company’s major corporate shareholder was AB.LV Private Equity Fund 2010, with a stake of 11.38%.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202012/31/2019Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Supervisory Council KirovsLipmans 79 12/23/2003 12/23/2003
Deputy Chairman of the Supervisory Council AnnaLipmane 71 5/25/2010 2/22/2008
Chief Finance and Administrative Officer, Investors Contact, Member of the Management Board JanisRomanovskis 59 1/12/2016 1/1/2003
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
HBM Pharma s.r.o. Sklabinska 30 Martin Sweden

Business Names
Business Name
GRD1R
Grindeks
Grindeks AS
HBM Pharma s.r.o.

General Information
Number of Employees: 1,505 (As of 12/31/2019)
Outstanding Shares: 9,585,000 (As of 9/30/2020)
Stock Exchange: RSE
Fax Number: +371 67083505


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023